ReviewRisk management and healthcare policy2026
Sepsis in Autoimmune Rheumatic Diseases: Risk Factors, Pathophysiology, and Outcomes.
Review in Risk management and healthcare policy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis remains a leading cause of morbidity and mortality in patients with autoimmune rheumatic diseases (ARDs), with distinct time-dependent outcomes that differ across disease subtypes, sepsis definitions, immune phenotypes, and follow-up time horizons. Chronic immune dysregulation, disease-specific cytokine signatures, cumulative organ damage, and dose- and duration-dependent immunosuppressive therapies render this population particularly vulnerable to sepsis. Evidence indicates that ARDs and sepsis share overlapping immunopathological mechanisms, including cytokine dysregulation, disease-dependent neutrophil extracellular trap (NET) abnormalities, Treg/Th17 imbalance, endotoxin-related immune tolerance, and phenotype-specific immune suppression. However, the functional consequences of these shared pathways diverge substantially by ARD subtype and disease activity. Whether ARDs independently influence sepsis susceptibility and clinical outcomes remains controversial, largely due to heterogeneity in sepsis definitions, endpoint variability, and incomplete confounder control. In this systematic review with narrative synthesis, conducted in accordance with PRISMA 2020 guidance (87 studies included), we synthesize current epidemiological, genetic, and mechanistic evidence and discuss risk-management and healthcare-policy implications. We summarize disease-related, immune-related, treatment-related, demographic, and healthcare-system risk factors, stratified by evidence strength and specificity to ARDs, and critically evaluate the time-dependent mortality paradox: preserved or improved short-term survival in certain ARDs versus substantially elevated long-term mortality. A deeper understanding of these complex interactions, including pathogen spectra, vaccination status, and modifiable risk factors, may facilitate the development of clinically actionable risk stratification tools, inform personalized therapeutic decision-making, and improve both short- and long-term outcomes in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.